Plasma Complement C3 Levels in Alzheimer's Disease

Lijun Wang,Jun Liu
DOI: https://doi.org/10.1002/alz.054786
2021-01-01
Alzheimer s & Dementia
Abstract:AbstractBackgroundAlzheimer's disease (AD) is closely related to the loss of synapses. It has been shown that the complement system is involved in the process of synaptic elimination. We investigated whether the levels of plasma complement C3 could be a probable biomarker for the prodromal and demented AD.MethodParticipants included 58 cognitively normal (CN) subjects, 395 patients with late mild cognitive impairment (LMCI), and 112 AD patients enrolled in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database in the current study.ResultThe results showed that plasma complement C3 levels were significantly increased in AD patients compared to LMCI and CN subjects. Negative correlations between plasma complement C3 and education, MMSE were observed in all subjects.ConclusionOur findings indicate that plasma complement C3 levels may not be a valuable biomarker for the diagnosis of AD in the prodromal and dementia stages. Further studies are needed to explore the diagnostic value of plasma complement C3 based on longitudinal population.
What problem does this paper attempt to address?